The Food and Drug Administration (FDA) has approved Kadcyla (ado-trastuzumab emtansine; Genentech) for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual ...

All of the women in the study had progressed on two or more HER2-targeted therapies, including Herceptin (trastuzumab) and Tykerb (lapatinib). Kadcyla (ado-trastuzumab emtansine; T-DM1) reduced the ...

The approval is based on data showing Kadcyla cut the risk of disease recurring by half compared to Herceptin in the adjuvant setting for specific patients with HER2-positive early breast cancer The ...

As its oncology stalwart Herceptin prepares for a rush of biosimilar competitors, Roche has high hopes for another horse in the HER2-positive breast cancer space. And now, Kadcyla’s ready to run in a ...

Roche’s Kadcyla needs some oomph, and the Swiss drugmaker’s new data might just do the trick. The company is teeing up a new filing for its next-generation breast cancer drug, hoping to gin up more ...

On the news, Kadcyla in this setting is now approved in 27 countries worldwide. The European Commission has approved Roche’s Kadcyla (trastuzumab emtansine) for the adjuvant (after surgery) treatment ...

– Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date – SOUTH SAN FRANCISCO, Calif. — Genentech, a member of the ...

The drug will be funded as an option for treating patients with HER2-positive early breast cancer NICE has published final guidance backing NHS use of Roche’s Kadcyla (trastuzumab emtansine) for the ...

– At three years, 88.3 percent of people treated with Kadcyla in the adjuvant HER2-positive early breast cancer setting did not have their breast cancer return compared to 77.0 percent treated with ...

Enhertu (trastuzumab deruxtecan), a HER2-targeting antibody-drug conjugate (ADC) bearing a deruxtecan (TOP1 inhibitor) warhead, was developed by Japanese pharmaceutical company Daichi Sankyo. A ...

ZURICH, Feb 5 () - Swiss drugmaker Roche aims to broaden the use of its Kadcyla breast cancer treatment as rivals crowd into the market with biosimilar copies of its older mainstay Herceptin. Roche ...

Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date 1,2 Long-term data also showed continued benefit in invasive ...